Starpharma Holdings Limited fined $93,240 for alleged unlawful advertising of Viraleze in relation to COVID-19 miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Creso Pharma’s strong quarter marks evolution into a broader-based pharmaceutical company: chairman
The surge in revenue along with business ties-ups across major global markets following regulatory changes and the acquisition of an established psychedelics company could transform it into a broader-based pharma company. CERES Natural Remedies flagship store in Vermont, US
Creso Pharma Ltd (ASX:CPH) (OTCMKTS:COPHF) (FRA:1X8) has witnessed a strong first quarter, with total revenue rising by 237% from the preceding quarter, marking the company’s evolution into a broader-based pharmaceutical company, according to non-executive chairman Adam Blumenthal.
The surge in the group’s revenue growth during the quarter highlighted the growing demand for the company’s products, as regulatory shifts across cannabis industries globally continue to unlock growth opportunities.
This article by Camila Ferezin was originally published on The Green Fund, and appears here with permission.
As medicinal cannabis products become more accessible in Australia, it becomes increasingly important to know how patients can access some themselves.
The Therapeutic Goods Administration (TGA) announced a final decision to down-schedule certain low dose cannabidiol (CBD) preparations from Schedule 4 (Prescription Medicine) to Schedule 3 (Pharmacist Only Medicine), allowing select medicinal cannabis products to be available over the counter.
The decision will allow TGA approved low-dose CBD containing products, up to a maximum of 150 mg/day, for use in adults, to be supplied over-the-counter by a pharmacist, without a prescription.
CBD medicines available for over-the-counter sale from 2021 miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Date Time
Over-the-counter access to low dose cannabidiol
Today the Therapeutic Goods Administration (TGA) announced a final decision to down-schedule certain low dose cannabidiol (CBD) preparations from Schedule 4 (Prescription Medicine) to Schedule 3 (Pharmacist Only Medicine).
The decision will allow low-dose CBD containing products, up to a maximum of 150 mg/day, for use in adults that have been approved by the TGA, to be supplied over-the-counter by a pharmacist, without a prescription. The decision limits over-the-counter supply to only those products that are approved by the TGA and included on the Australian Register of Therapeutic Goods (ARTG). The decision also outlines additional limits on dosage form and packaging requirements, including pack size and child resistant closures.